Table 4.
Change in Tissue Factor Pathway Inhibitor and Activated Protein C Resistance from Baseline to Year 1
| Median (Interquartile Range) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Estrogen Trial | Estrogen + Progestin Trial | ||||||||
| CEE | CEE Placebo | CEE+MPA | CEE+MPA Placebo | P Value for Change* | |||||
| N | Median (IQR) | N | Median (IQR) | N | Median (IQR) | N | Median (IQR) | ||
| Total TFPI, ng/mL | 226 | -18.10 (21.70) | 207 | -1.40 (16.60) | 195 | -17.40 (19.00) | 154 | -1.40 (15.40) | <0.001 |
| Free TFPI, ng/mL | 226 | -3.60 (8.00) | 207 | 0.20 (6.90) | 195 | -3.10 (6.40) | 154 | 0.30 (6.10) | <0.001 |
| TFPI Activity, % | 225 | -27.00 (30.00) | 207 | -4.00 (22.00) | 195 | -25.00 (29.00) | 154 | 0.00 (19.00) | <0.001 |
| nAPCsr, ratio | 147 | 1.60 (3.22) | 147 | -0.16 (2.16) | 128 | 1.45 (2.54) | 128 | 0.14 (1.73) | <0.001 |
*
P values are from a paired t test (per participant) of change in biomarker in combined trials during hormone treatment compared to control adjusted for hysterectomy status, baseline levels of biomarkers, and the same covariates as in Table 3.